Study in Human iPSCs-derived RPE Cells Transplantation for Advanced (Late-stage) AMD

StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 6 months later Jun 1, 2028 → Dec 31, 2028
Primary endpoint reworded 1 of 1 changed
See other at-risk trials from The First Affiliated Hospital with Nanjing Medical University

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jun 1, 2028 to Dec 31, 2028 Show 10 more changesShow less
    • Primary endpoint(s) modified
    • Recruitment opened
    • Enrollment increased: 9 → 12 participants
    • Interventions modified
    • Start date changed from estimate of Feb 10, 2026 to Oct 14, 2025
    • Eligibility criteria expanded, about 24 words
    • Secondary endpoints revised (2)
    • Site details revised
    • Collaborators expanded, about 4 words
    • Study title expanded, about 1 word
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Phase I Study of the Safety and Preliminary Efficacy of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.
Trial Details
NCT Number NCT07418177
Lead Sponsor The First Affiliated Hospital with Nanjing Medical University
Collaborators: HELP Therapeutics Co., Ltd.
Conditions
(from sponsor)		 AMD - Age-Related Macular Degeneration
Related terms Geographic Atrophy, Macular Degeneration
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov